Terumo Corporation

Terumo Corporation (TYO: 4543) is a global medical device company headquartered in Japan. The company has been listed on the Tokyo Stock Exchange since 1982. Terumo had ~5,900 patents as of March 2021 and generated revenue of JPY 921.9 billion (~USD 6 billion) in FY2024 (year ending March 31).

Terumo operates under three divisions: 

1) The Cardiac and Vascular division , which includes medical devices that involve the heart, lungs, and blood vessels, such as interventional systems, oxygenators, and vascular graft products.

2) The Medical Care Solutions division , which provides a range of medical equipment and devices under hospital care (syringes, infusion pumps, etc.), life care (blood glucose monitoring systems, blood pressure monitors, digital thermometers, etc.), and pharmaceutical (prefilled syringes, needles, etc.) segments.

3) The Blood and Cell Technologies division , which offers equipment for blood centers and cell and gene therapy research. 

Terumo’s largest individual markets are the US (~30% of total revenue in FY2024) and Japan (~23%). Its medium- to long-term plans include strengthening its existing businesses and investing in the future during FY2022–FY2026, strengthening the corporate foundation and generating profit from high-growth businesses during FY2027–FY2031, and leading a paradigm shift in medical care beyond FY2032. Terumo expects to reach JPY 1 trillion in revenue, maintaining a high single-digit revenue growth over FY2021–FY2026. Terumo expects to achieve carbon neutrality by 2040.